When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. GSK to cap out-of-pocket inhaler costs in US - AOL

   www.aol.com/news/gsk-cap-pocket-inhaler-costs...

   The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

3. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

4. Ozempic, Trulicity among Medicare's priciest drugs, report finds

   www.aol.com/news/ozempic-trulicity-among-medic...

   List prices on 20 of the drugs increased faster than the rate of inflation. Under the 2022 federal law, drugmakers must pay rebates to Medicare if list prices increase faster than inflation.

5. Prescription drug prices in the United States - Wikipedia

   en.wikipedia.org/wiki/Prescription_drug_prices...

   Prescription drug list prices in the United States continually are among the highest in the world. [1] [2] The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015.

6. Umeclidinium bromide - Wikipedia

   en.wikipedia.org/wiki/Umeclidinium_bromide

   Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3]

7. Analysis-Ozempic on Wall Street's list for 2027 ... - AOL

   www.aol.com/news/analysis-ozempic-wall-streets...

   Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026, Wall Street analysts are betting on a 2027 list that will include Novo Nordisk's blockbuster ...